Back to top

DELIVER Logo

 

 

 

 

 

 

 

MTN-042/DELIVER – A Phase IIIb open-label study designed to evaluate the safety and acceptability of the monthly dapivirine vaginal ring, which is under regulatory review, and Truvada as daily PrEP in pregnant women. The study, which launched in South Africa in early 2020, will enroll 750 women at different times during pregnancy who will use either the dapivirine ring or Truvada as PrEP until they deliver. Women will be followed for six weeks postpartum, and their babies will be followed for one year. Other trial sites are in Malawi, Uganda and Zimbabwe. The study is the first of the ring in pregnant women and will provide more insight about the safety of Truvada as PrEP during pregnancy, a time when women are at much greater risk of HIV.

Questions and Answers - The DELIVER and B-PROTECTED Studies
2-May-2021

10,000-plus medical charts provides comparator for HIV prevention study in pregnant women
31-March-2021

Fact Sheet: The MTN-042B Sub-study of DELIVER (MTN-042)
31-March-2021

The DELIVER and B-PROTECTED Studies: Preventing HIV in Pregnant and Breastfeeding Women
08-September-2020

Researchers launch DELIVER study to assess safety of PrEP and dapivirine vaginal ring in pregnant women
10-February-2020

Video about DELIVER and B-PROTECTED in English
DELIVER and B-PROTECTED Video Image

 

 

 

 


Video about DELIVER and B-PROTECTED in Zulu
DELIVER and B-PROTECTED Video Image in Zulu

 

 

 




Video about DELIVER and B-PROTECTED in Luganda
DELIVER and B-PROTECTED Video Image in Luganda

 

 

 

 


Video about DELIVER and B-PROTECTED in Shona
DELIVER and B-PROTECTED Video Image in Shona

 

 

 




Video about DELIVER and B-PROTECTED in Chichewa
Video about DELIVER and B-PROTECTED Image in Chichewa


 

 

 

 

See Also
MTN-042 Study Page

Meeting Report: Stakeholders Consultation on MTN-042

MTN-042B Study Page

MTN-043 (B-PROTECTED) Study Page